Armour Thyroid is not recommended by most major medical guidelines because it has never been approved by the FDA, delivers a higher proportion of the faster-acting thyroid hormone T3 than the human body naturally produces, and makes blood test monitoring more difficult. An estimated 1.5 million patients in the U.S. still received prescriptions for it and similar products in 2024, but the FDA has recently taken steps toward pulling these medications from the market entirely.
It Was Never FDA Approved
Armour Thyroid is made from dried, ground pig thyroid glands, a type of medication called desiccated thyroid extract (DTE). It was the original treatment for hypothyroidism, used long before synthetic thyroid hormones existed. Because it predates the modern drug approval process and is animal-derived, it was essentially grandfathered into the market without ever going through FDA review for safety, purity, or potency.
That distinction matters more than it might seem. FDA-approved drugs must prove in clinical trials that they work consistently, that each batch contains the same amount of active ingredient, and that the manufacturing process meets specific quality standards. Armour Thyroid and other DTE products like NP Thyroid and Nature-Throid have never been held to those standards. The FDA has stated it has concerns about the safety and effectiveness of these unapproved products precisely because they haven’t undergone that review. In March 2026, the FDA informed manufacturers of its intent to issue guidance on compliance priorities, signaling a potential path toward removing unapproved DTE products from the market unless manufacturers submit formal applications for approval.
The T3 Problem
Your thyroid gland produces two hormones: T4, which is relatively slow-acting and long-lasting, and T3, which is fast-acting and potent. In a healthy human thyroid, the ratio heavily favors T4. Your body then converts T4 into T3 as needed throughout the day, maintaining steady levels.
Armour Thyroid comes from pig thyroid glands, and pigs produce a significantly higher proportion of T3 relative to T4 than humans do. When you take a dose, T3 is almost completely absorbed within about four hours. That rapid spike means your T3 levels surge above normal shortly after each dose, then drop off. This creates a roller-coaster pattern rather than the steady hormone levels that synthetic T4 provides when taken daily.
That T3 spike is the core pharmacological concern. Repeatedly elevated T3 levels, even briefly, can push the body into a mildly hyperthyroid state. Over time, this carries real risks. Elevated T3 is associated with a higher chance of cardiac arrhythmias, particularly atrial fibrillation, which is more common in people with what’s called T3 toxicosis. Combination T4/T3 therapy is specifically not recommended for patients prone to heart rhythm problems, because the extra T3 can act as a trigger. There are also long-standing concerns about accelerated bone density loss, especially in postmenopausal women, when thyroid hormone levels run consistently high.
Lab Monitoring Gets Complicated
The standard way to manage hypothyroidism is straightforward: your doctor checks your TSH level, adjusts your dose of synthetic T4 if needed, and rechecks. TSH is a reliable marker because T4 is absorbed slowly and maintains stable blood levels throughout the day.
Armour Thyroid disrupts this system. The T3 component can suppress TSH readings, making it look like you’re getting too much thyroid hormone even when your T4 levels appear normal. Excess desiccated thyroid extract is listed as a recognized cause of subclinical hyperthyroidism, a condition where TSH runs low without obvious symptoms but still carries cardiovascular risks over time. For clinicians, this makes it harder to distinguish between a patient who is properly dosed, slightly overdosed, or developing a separate thyroid problem. The timing of blood draws relative to when you took your dose also affects results, adding another layer of uncertainty.
Why Some Patients Still Prefer It
Despite the guideline warnings, patient preference for Armour Thyroid is not trivial. In a crossover study of 70 hypothyroid patients who tried both DTE and synthetic T4 for several months each, 49% preferred desiccated thyroid extract, compared to just 19% who preferred levothyroxine. About 23% had no preference. DTE use was also associated with more weight loss during the study period.
Interestingly, though, objective measures told a different story. There was no measurable difference in psychometric testing or symptom scores between the two treatments. This suggests the preference may be driven by subjective factors like modest weight changes or the appeal of a “natural” product rather than a clear clinical advantage. It’s worth noting that feeling better on a medication is meaningful to the person taking it, but it doesn’t override the safety and consistency concerns that drive guideline recommendations.
What the Regulatory Shift Means for Patients
The FDA’s recent actions represent the most significant regulatory threat Armour Thyroid has faced. The agency has proposed that DTE manufacturers submit formal applications for approval as biological products. If manufacturers don’t comply, or if their products can’t meet approval standards, these medications could be pulled from pharmacies.
For the roughly 1.5 million patients currently taking DTE products, this could mean a mandatory switch to synthetic thyroid hormone. Synthetic T4 (levothyroxine) remains the guideline-recommended first-line treatment and is the most prescribed thyroid medication worldwide. For patients who have struggled on levothyroxine alone, some endocrinologists prescribe a carefully dosed combination of synthetic T4 and synthetic T3, which allows for precise control of the T3 component without the batch-to-batch variability and supraphysiologic T3 peaks that come with animal-derived products.
If you’re currently taking Armour Thyroid or a similar DTE product, the regulatory timeline suggests changes could begin taking shape by late 2026. Talking with your prescribing doctor about a transition plan before supply disruptions occur is a practical step.